Skip to main content
LUSHANG FREDA PHARMACEUTICAL CO.,LTD. logo

LUSHANG FREDA PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 600223 ISIN · CNE000001147 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,828 across all filing types
Latest filing 2025-08-21 Governance Information
Country CN China
Listing Shanghai Stock Exchange 600223

About LUSHANG FREDA PHARMACEUTICAL CO.,LTD.

http://www.lshfreda.com/

Lushang Freda Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, health supplements, and high-end cosmetics. The company is recognized as a global leader in the production of sodium hyaluronate (hyaluronic acid), utilizing advanced fermentation technology to supply raw materials for medical, food, and cosmetic applications. Its product portfolio spans several therapeutic areas, including ophthalmology, orthopedics, and dermatology, with a significant focus on medical aesthetics and functional skincare. By integrating biotechnology with industrial-scale production, the company maintains a comprehensive supply chain that supports both its proprietary brands and international B2B partnerships. Key operations involve the synthesis of bioactive substances and the formulation of specialized treatments designed to improve skin health and joint mobility.

Recent filings

Filing Released Lang Actions
鲁商福瑞达医药股份有限公司董事会议事规则
Governance Information Classification · 95% confidence The document is titled as the "Rules of Procedure for the Board of Directors" of 鲁商福瑞达医药股份有限公司. It details the governance structure, meeting procedures, voting rules, committee compositions, and other internal rules related to the board's operation. There is no financial data, no mention of financial results, no audit information, no voting results announcement, no legal proceedings, no capital changes, no earnings release, and no investor presentation. The content is focused on governance practices and internal rules of the board. Therefore, this document fits the category of Governance Information (CGR). The document length is sufficient and it is not a mere announcement or certification, so it is not RPA or RNS. Hence, the classification is CGR with high confidence.
2025-08-21 Chinese
鲁商福瑞达医药股份有限公司2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "鲁商福瑞达医药股份有限公司2025 年半年度报告" which translates to "Lushang Freda Pharmaceutical Co., Ltd. 2025 Semi-Annual Report." It covers the period from January 1, 2025 to June 30, 2025, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, profit, cash flow, and segment performance, as well as management discussion and analysis, business overview, and operational details. The document is comprehensive and contains actual financial statements and substantive financial analysis. It is not merely an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-21 Chinese
鲁商福瑞达医药股份有限公司董事离职管理制度
Board/Management Information Classification · 95% confidence The document is titled '鲁商福瑞达医药股份有限公司董事离职管理制度' which translates to 'Board Director Resignation Management System' of the company. It details the procedures, principles, responsibilities, and obligations related to the resignation and departure of company directors. The content focuses on governance rules and internal management policies regarding board members leaving the company. There is no financial data, no audit information, no earnings or capital updates, no voting results, no legal proceedings, and no shareholder transactions. The document is a governance-related internal policy document about board and senior management changes, specifically about director resignation management. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements or information about changes in the company's board or senior management.
2025-08-21 Chinese
鲁商福瑞达医药股份有限公司独立董事年报工作制度
Governance Information Classification · 95% confidence The document is titled as an 'Independent Director Annual Report Work System' for a company, describing the duties and responsibilities of independent directors in the preparation and supervision of the company's annual report. It outlines governance and internal control mechanisms related to the annual report process, including communication with auditors and confidentiality. The document is a governance-related policy or procedural document rather than the annual report itself or an announcement. It does not contain financial data or audit results but focuses on governance practices related to the annual report. Therefore, it fits best under Governance Information (CGR). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2025-08-21 Chinese
鲁商福瑞达医药股份有限公司年报信息披露重大差错责任追究制度
Governance Information Classification · 95% confidence The document is a formal internal policy titled '年报信息披露重大差错责任追究制度' which translates to 'Annual Report Information Disclosure Major Error Responsibility Pursuit System'. It outlines the principles, responsibilities, and disciplinary measures related to errors in the annual report information disclosure. It references laws and regulations related to annual reports but does not contain any actual financial data or the annual report itself. The document is a governance or compliance policy related to annual report disclosures rather than the annual report or an announcement of it. Given the content focuses on governance and internal control over annual report disclosures, the most appropriate classification is Governance Information (CGR). The document length is short (1646 characters), and it is not an announcement or certification but a policy document, so it does not fit into RPA or RNS. Therefore, the classification is CGR with high confidence.
2025-08-21 Chinese
鲁商福瑞达医药股份有限公司董事和高级管理人员所持本公司股份及其变动管理制度
Director's Dealing Classification · 95% confidence The document is titled as a management system for the holdings and changes of shares by the company's directors and senior management. It details rules and procedures regarding the declaration, locking, unlocking, and trading restrictions of shares held by directors and senior executives. It references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Shanghai Stock Exchange. The content is focused on governance and compliance related to insider shareholdings and transactions by directors and senior management. It is not a financial report, earnings release, or announcement of voting results. It is not a proxy statement or remuneration report. The document is a governance-related internal regulation concerning board and management shareholding and trading. Therefore, the most appropriate classification is "Director's Dealing (DIRS)", which covers reports of personal share transactions by company directors and executives, including their management and regulatory compliance related to such holdings and transactions. The document length is sufficient and contains substantive content, not just an announcement or certification. Confidence is high due to clear focus on director and senior management shareholding management rules.
2025-08-21 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.